Selena Chacon
Universidad de Costa Rica
Stephen Fesik lab
I'm working on the development of small molecules that are capable of disrupting the interaction between WDR5-MYC. MYC is an oncoprotein that is overexposes in multiple cancers and has been a key target in the past ~30 years. Unfortunately, the prevailing approaches for the treatment of MYC-driven cancer patients still involves non-specific cytotoxic drugs, surgery and radiation.